#1 Clinical Trials Search in Europe

Lenograstim

Lenograstim, a granulocyte colony-stimulating factor (G-CSF), is being studied in various clinical trials for its potential in cancer treatment and stem cell mobilization. This article explores the use of Lenograstim in different medical scenarios, including its role in managing chemotherapy-induced neutropenia, mobilizing stem cells for transplantation, and supporting patients with hematological disorders. We’ll examine the latest research and findings from these clinical trials to better understand how Lenograstim may benefit patients in the future.

Table of Contents

What is Lenograstim?

Lenograstim is a medication that belongs to a class of drugs known as granulocyte colony-stimulating factors (G-CSFs). It is also referred to by its brand name Granocyte[1]. Lenograstim is a synthetic version of a naturally occurring protein in your body that stimulates the production of certain white blood cells[2].

How Lenograstim Works

Lenograstim works by stimulating the bone marrow to produce more neutrophils, which are a type of white blood cell crucial for fighting infections. It also helps these cells survive longer and increases their activity in the body[3]. This medication is particularly useful in situations where the body’s natural neutrophil production is compromised, such as during chemotherapy treatment.

Medical Conditions Treated with Lenograstim

Lenograstim is used to treat or prevent several medical conditions, including:

  • Neutropenia: A condition characterized by an abnormally low number of neutrophils in the blood. This often occurs as a side effect of chemotherapy[1].
  • Febrile Neutropenia: A serious condition where a patient with neutropenia develops a fever, indicating a possible infection[4].
  • Stem Cell Mobilization: Lenograstim is used to help collect stem cells from the blood for transplantation in patients with certain types of cancer, such as multiple myeloma[5].
  • Acute Myeloid Leukemia (AML): It’s used as part of the treatment regimen for patients with this type of blood cancer[6].

Administration and Dosage

Lenograstim is typically administered as a subcutaneous injection, which means it’s injected just under the skin. In some cases, it may be given intravenously (directly into a vein)[2]. The dosage and duration of treatment can vary depending on the specific condition being treated and the patient’s individual needs. For example:

  • For chemotherapy-induced neutropenia, it’s often given daily until the neutrophil count recovers[1].
  • For stem cell mobilization, it may be given for several days before the collection procedure[5].
  • In clinical trials, doses have ranged from 5 to 10 micrograms per kilogram of body weight per day[3].

Clinical Trials and Research

Lenograstim has been the subject of numerous clinical trials to evaluate its effectiveness in various conditions:

  • A study compared Lenograstim to Filgrastim (another G-CSF) for stem cell mobilization in multiple myeloma patients[4].
  • Research has been conducted on using Lenograstim to mobilize stem cells in healthy volunteers for donation purposes[2].
  • Clinical trials have explored the use of Lenograstim in combination with chemotherapy for acute myeloid leukemia treatment[6].

Side Effects and Safety

While Lenograstim is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Bone pain
  • Headache
  • Fatigue
  • Nausea
  • Skin reactions at the injection site

In rare cases, more serious side effects can occur. It’s important to discuss potential risks and side effects with your healthcare provider before starting treatment with Lenograstim[1][3].

Aspect Details
Primary Uses Stem cell mobilization, Management of chemotherapy-induced neutropenia, Support in hematological disorders
Administration Typically subcutaneous injection, Dosage varies by condition and trial
Key Benefits Reduces risk of neutropenia and infections, Improves chemotherapy adherence, Enhances stem cell collection for transplantation
Studied Conditions Multiple myeloma, Acute myeloid leukemia, Solid tumors, Castration-resistant prostate cancer
Notable Trials MEL-CAP study (prostate cancer), Azacitidine vs. Fludarabine/Cytarabine (AML), Pharmacokinetic study in multiple myeloma
Safety Profile Generally well-tolerated, Common side effects include bone pain and flu-like symptoms, Rare serious side effects monitored in trials

FAQ

  • What is Lenograstim and how does it work? Lenograstim is a type of granulocyte colony-stimulating factor (G-CSF). It works by stimulating the bone marrow to produce more white blood cells, particularly neutrophils. This helps to boost the immune system and fight infections, especially in patients undergoing chemotherapy or stem cell transplantation.
  • In which medical conditions is Lenograstim being studied? Lenograstim is being studied in various conditions, including chemotherapy-induced neutropenia in cancer patients, stem cell mobilization for transplantation in multiple myeloma patients, and as a supportive treatment in acute myeloid leukemia. It's also being investigated for its potential in improving outcomes for patients with solid tumors.
  • How is Lenograstim administered in clinical trials? In most clinical trials, Lenograstim is administered subcutaneously (under the skin). The dosage and duration of treatment vary depending on the specific trial and condition being studied. For example, in stem cell mobilization trials, it may be given for several days before cell collection, while in chemotherapy support, it might be given after each chemotherapy cycle.
  • What are the potential benefits of using Lenograstim in cancer treatment? Potential benefits of Lenograstim in cancer treatment include reducing the risk and severity of neutropenia (low white blood cell count) after chemotherapy, which can help prevent infections. It may also allow for better adherence to chemotherapy schedules by reducing treatment delays or dose reductions due to low blood cell counts.
  • Are there any side effects associated with Lenograstim use in clinical trials? While Lenograstim is generally well-tolerated, some side effects have been reported in clinical trials. These may include bone pain, headache, and mild flu-like symptoms. In rare cases, more serious side effects such as spleen enlargement or rupture have been observed. It's important to note that the safety profile is closely monitored in all clinical trials.

Ongoing Clinical Trials on Lenograstim

  • Study of Ponatinib and Chemotherapy for Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on Improving Treatment for Young Adults with Poor-Prognosis Non-Seminomatous Germ-Cell Tumors Using Paclitaxel and Drug Combination

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on the Use of OTL-103 Gene Therapy and Drug Combination for Patients with Wiskott-Aldrich Syndrome

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • A Study of Gene Therapy Using Modified Stem Cells for Patients with Transfusion-Dependent Beta-Thalassemia Who Need Regular Blood Transfusions

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Melphalan and Drug Combination for Low and Intermediate Risk Neuroblastoma Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Gene Therapy with Autologous Stem Cells and Drug Combination for Children with Mucopolysaccharidosis Type I Hurler Variant

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study on the Safety and Effects of Temferon for Patients with Metastatic Renal Cell Carcinoma Using a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

Glossary

  • Lenograstim: A type of granulocyte colony-stimulating factor (G-CSF) used to stimulate the production of white blood cells, particularly neutrophils, in the bone marrow.
  • Neutropenia: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important for fighting infections.
  • Stem Cell Mobilization: The process of moving stem cells from the bone marrow into the bloodstream, where they can be collected for transplantation.
  • Granulocyte Colony-Stimulating Factor (G-CSF): A protein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
  • Autologous Stem Cell Transplantation: A procedure where a patient's own stem cells are collected, stored, and later reinfused to restore blood cell production after high-dose chemotherapy.
  • Febrile Neutropenia: A condition where a patient has both a fever and an abnormally low number of neutrophils, indicating a high risk of infection.
  • Chemotherapy-Induced Neutropenia: A decrease in neutrophil count caused by chemotherapy, which can increase the risk of infections in cancer patients.
  • CD34+ Cells: A type of cell that includes blood stem cells, which can develop into different types of blood cells.
  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by the rapid growth of abnormal white blood cells.
  • Multiple Myeloma: A cancer of plasma cells, a type of white blood cell that normally produces antibodies.

References

  1. https://clinicaltrials.gov/study/NCT01107756
  2. https://clinicaltrials.gov/study/NCT05594433
  3. https://clinicaltrials.gov/study/NCT03498248
  4. https://clinicaltrials.gov/study/NCT00932217
  5. https://clinicaltrials.gov/study/NCT02184897
  6. https://clinicaltrials.gov/study/NCT02319135